9.89 USD
▲+0.45+4.77%
盘后 10.10 0.00%
2026-09-16
市值
$101.48M
市盈率
—
EPS
-1.19
股息率
—
52 周区间
3.92 – 19.15
成交量
46.94K
Beta
0.11
目标价
13.67
52W 低 3.9252W 高 19.15
价格走势
公司简介
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. T...